Fractyl ais a biotechnology company looking to bring curative therapies to the large populations of patients with metabolic disease.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/16/2021 | Series F | $100MM | $xx.xx | $87.29B | M28 Capital, Maverick Capital, Population Health Partners | |
Price per Share
$xx.xx
Shares Outstanding
11,927,048
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
M28 Capital, Maverick Capital, Population Health Partners
|
||||||
08/06/2020 | Series E | $55.07MM | $xx.xx | $37.85B | Bessemer Venture Partners, Catalio Capital Management, Cdib Venture Capital, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Mithril Capital Management, Taiwania Capital Management Corporation, True Ventures, Yj Capital | |
Price per Share
$xx.xx
Shares Outstanding
12,838,573
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Catalio Capital Management, Cdib Venture Capital, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Mithril Capital Management, Taiwania Capital Management Corporation, True Ventures, Yj Capital
|
||||||
11/30/2017 | Series D | $43.98MM | $xx.xx | $26.08B | Bessemer Venture Partners, Deerfield Management Company, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Ido Fund, Mithril Capital Management, True Ventures | |
Price per Share
$xx.xx
Shares Outstanding
11,994,461
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Deerfield Management Company, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Ido Fund, Mithril Capital Management, True Ventures
|
||||||
11/19/2015 | Series C-1 | $20.26MM | $xx.xx | $16.96B | Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril | |
Price per Share
$xx.xx
Shares Outstanding
9,064,640
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril
|
||||||
11/19/2015 | Series C-2 | $47.17MM | $xx.xx | $16.96B | Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril | |
Price per Share
$xx.xx
Shares Outstanding
15,336,464
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril
|
||||||
03/21/2013 | Series B | $14.5MM | $xx.xx | $2.86B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
11,451,453
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
06/15/2011 | Series A | $5.5MM | $xx.xx | $1.1B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|